United States: HHS Issues Guidance On Communications About Drugs And Biologics Under HIPAA And HITECH

Last Updated: September 26 2013
Article by Jennifer J. Daniels

Just in time for the September 23 enforcement deadline under the HIPAA Omnibus Final Rule, the Department of Health and Human Services ("HHS") Office of Civil Rights ("OCR") has issued Guidance (the "Guidance") regarding communications with individuals about drugs or biologics.

You may recall that the Final Rule requires that a covered entity obtain an authorization for all treatment and healthcare operations communications where the covered entity receives financial remuneration for making the communication from the third party whose product or service is described in the communication. There is no general exception for treatment communications, but there is an exception for refill reminders or other communications about a drug or biologic currently being prescribed to the individual, so long as the financial remuneration paid to the covered entity is reasonably related to the covered entity's cost of making the communication.

The Guidance reinforces some concepts that were already discussed by OCR in the preamble to the Final Rule (which are covered at the end of this Alert), but some interpretations by OCR in this Guidance are new:

  1. Delay in Enforcement: Since the publication of the Final Rule, OCR has come under attack from adherence program vendors, pharmacies, and the Specialty Pharmacy Association of America for having gone too far in restricting refill reminders and adherence communications. Adheris Inc., a vendor to pharmaceutical manufacturers that sends refill reminders and adherence communications, brought suit against the agency and sought a preliminary injunction against the implementation of the Final Rule on September 23. OCR argued to the court that no injunction was necessary because it had decided to suspend enforcement of its restrictions on refill reminders and other communications until November in anticipation of the issuance of this Guidance.
    Oddly, the main body of the Guidance does not include a general statement indicating OCR's intent to delay enforcement of the Final Rule with respect to manufacturer-funded refill reminder and adherence communications. Rather, OCR raises the delay in enforcement in response to an FAQ regarding a specialty pharmacy program that makes manufacturer-sponsored communications to patients for prescribed drugs for chronic and complex diseases that require complicated therapies. The pharmacy in the FAQ has taken the approach with new patients of getting authorizations when they enroll in the program, but existing patients have not signed such authorizations. The FAQ asks whether existing patients must either sign authorizations or be terminated from the program. OCR responded that it will not determine that a covered entity is in violation of the marketing provisions of the Final Rule where authorizations are not obtained by the covered entity from existing patients to whom it is making such communications by September 23, 2013, so long as (i) the patients from whom authorizations have not been obtained have not opted out of or objected to the receipt of the communications, and (ii) the authorizations are obtained by the next time their prescriptions are renewed or by September 23, 2014, whichever is earlier. Presumably this delay in enforcement with respect to the "marketing provisions" applies only to the refill reminder exception, and does not apply more broadly to the larger change in the Final Rule that expanded marketing to include communications about a product where remuneration is received by a third party (though this is not entirely clear). Further, it seems from OCR's response that this delay in enforcement applies to all refill reminders or other communications about drugs or biologics that are currently prescribed to the individual, and not just to these programs geared toward individuals who require complex drug therapies (but, again, it is not entirely clear).
  2. Fair Market Value Payment to a Business Associate: OCR explains in the Guidance that remuneration is acceptable under the marketing exception (and "reasonably related" to the covered entity's cost of making the communication) if it involves payments made to a business associate carrying out the communication and such payments are no more than the fair market value of the business associate's services. Further, such payments may be made directly by the manufacturer to the business associate or through the covered entity to the business associate. Accordingly, while the exception does not permit the covered entity to make a profit from making such communications, the business associate may make a profit so long as the business associate is only charging a fair market value fee for its services. This change in interpretation by OCR may give business associates like Adheris some new comfort, so long as they are charging a fee for their services that a third party would pay in an arms-length transaction.
  3. Costs of Capital and Overhead are Reasonably Related to the Cost of Making the Communication: A communication about a drug or biologic currently being prescribed to the individual is not marketing, so long as any remuneration received by the covered entity from the manufacturer is reasonably related to the cost of making the communication. In the preamble to the Final Rule, OCR stated that it considered permissible costs for which a covered entity could receive remuneration under the exception to be those that covered only the costs of labor, supplies and postage to make the communication. OCR stated, "Where the financial remuneration ... generates a profit or includes payment for other costs, such financial remuneration would run afoul of the Act's 'reasonable in amount' language." In the Guidance, OCR states that a payment is "reasonable in amount" if it covers labor, materials, and supplies, as well as capital and overhead costs. Including capital and overhead costs is an expansion of OCR's interpretation of the types of costs that were permitted under the preamble to the Final Rule.
  4. Recently Lapsed Prescriptions: The exception to the marketing rule is for communications about drugs or biologics that are "currently prescribed" to the individual. In the Guidance, OCR clarifies that this includes communications about a recently lapsed prescription, so long as the prescription has lapsed within the last 90 calendar days.
  5. New Formulations of Currently Prescribed Drugs: OCR explains in the Guidance that communications about new formulations of a currently prescribed medicine do not fall within the marketing exception for communications about currently prescribed drugs. However, OCR explains that a pharmacy could send an adherence communication to an individual that is permitted by the exception without an authorization, and then also include information in that same communication about the availability of a product with a more convenient dosing schedule or in a liquid form without naming the particular medication, and this would not be considered marketing. This interpretation could open some possibilities for marketing communications that do not name the specific product being marketed.
  6. Risk Evaluation and Mitigation Strategy ("REMS") Communications: OCR makes clear in the Guidance that communications by a covered entity to a patient about a prescribed drug that are required by the FDA under a REMS program are not marketing, even if they are funded by the manufacturer.

As noted above, the Guidance covers some of the same ground that was already discussed in the preamble to the Final Rule, including:

  1. Drug Delivery Systems: Where an individual is prescribed a self-administered drug or biologic, communications regarding all aspects of the drug delivery system, including, for example, an insulin pump, fall within the exception for communications about a drug or biologic that is currently prescribed to the individual.
  2. Face-to-Face Communications: Face-to-face communications are not marketing. So, if the pharmacist provides a refill reminder to a patient face-to-face, no authorization is required even if the pharmacy receives financial remuneration that is in excess of the pharmacy's costs. Similarly, a manufacturer can provide a physician with pamphlets about the manufacturer's product, and the physician can distribute those pamphlets when meeting with patients in his or her office without an authorization, even if the physician is paid by the manufacturer to make the communication. The same communication over the phone or by mail would require an authorization.
  3. In-Kind Benefits Not Remuneration: OCR again emphasizes that financial remuneration does not include non-financial compensation, such as in-kind benefits provided to the covered entity in exchange for making a communication about a product or service. Rather, financial remuneration is payment made in exchange for the communication.
  4. Payment Not from Manufacturer Is Not Remuneration: If payment is made for the communication from a third party who is not the party whose product or service is being promoted, such as a health plan paying for the communication by a health care provider, then the communication is not marketing. "Financial remuneration" is "direct or indirect payment from or on behalf of a third party whose product or service is being described."
  5. Communications about Generic Equivalents: OCR restates that communications about a generic equivalent of the drug currently prescribed to the individual falls within the marketing exception for communications about a currently prescribed medication.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Jennifer J. Daniels
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Emails

From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.